CA3222837A1 - Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same - Google Patents
Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same Download PDFInfo
- Publication number
- CA3222837A1 CA3222837A1 CA3222837A CA3222837A CA3222837A1 CA 3222837 A1 CA3222837 A1 CA 3222837A1 CA 3222837 A CA3222837 A CA 3222837A CA 3222837 A CA3222837 A CA 3222837A CA 3222837 A1 CA3222837 A1 CA 3222837A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- oxadiazol
- pyridazin
- aliphatic
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208918P | 2021-06-09 | 2021-06-09 | |
| US63/208,918 | 2021-06-09 | ||
| PCT/US2022/032798 WO2022261296A1 (en) | 2021-06-09 | 2022-06-09 | Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3222837A1 true CA3222837A1 (en) | 2022-12-15 |
Family
ID=82492690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3222837A Pending CA3222837A1 (en) | 2021-06-09 | 2022-06-09 | Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240287054A1 (https=) |
| EP (1) | EP4352054A1 (https=) |
| JP (1) | JP2024522183A (https=) |
| AU (1) | AU2022288631A1 (https=) |
| CA (1) | CA3222837A1 (https=) |
| WO (1) | WO2022261296A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025184571A1 (en) * | 2024-03-01 | 2025-09-04 | City Of Hope | Pcna inhibitors for the treatment of myc family associated cancers |
| GB202414345D0 (en) * | 2024-09-30 | 2024-11-13 | Mycural Therapeutics Ab | New compounds and medical uses thereof |
| GB202414337D0 (en) * | 2024-09-30 | 2024-11-13 | Mycural Therapeutics Ab | New compounds and medical uses thereof |
| GB202414343D0 (en) * | 2024-09-30 | 2024-11-13 | Mycural Therapeutics Ab | New compounds and medical uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| EP2304366A2 (en) * | 2008-05-30 | 2011-04-06 | Foster Wheeler Energia Oy | Method of and system for generating power by oxyfuel combustion |
| US10463649B2 (en) * | 2015-06-08 | 2019-11-05 | Texas Tech University System | Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors |
-
2022
- 2022-06-09 US US18/568,738 patent/US20240287054A1/en active Pending
- 2022-06-09 WO PCT/US2022/032798 patent/WO2022261296A1/en not_active Ceased
- 2022-06-09 AU AU2022288631A patent/AU2022288631A1/en active Pending
- 2022-06-09 JP JP2023575827A patent/JP2024522183A/ja active Pending
- 2022-06-09 EP EP22741091.7A patent/EP4352054A1/en active Pending
- 2022-06-09 CA CA3222837A patent/CA3222837A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024522183A (ja) | 2024-06-11 |
| EP4352054A1 (en) | 2024-04-17 |
| AU2022288631A1 (en) | 2024-01-18 |
| WO2022261296A1 (en) | 2022-12-15 |
| US20240287054A1 (en) | 2024-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240287054A1 (en) | Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same | |
| CN108314677B (zh) | 一种ezh2抑制剂及其用途 | |
| KR101749192B1 (ko) | 트리아진, 피리미딘 및 피리딘 유사체 및 이의 치료제 및 진단 프로브로의 용도 | |
| WO2020160192A1 (en) | Compounds and uses thereof | |
| US11014902B2 (en) | MYC G-quadruplex stabilizing small molecules and their use | |
| KR20200010306A (ko) | Kras의 공유적 억제제 | |
| RS63156B1 (sr) | Novi derivati heteroaril amida kao selektivni inhibitori histon deacetilaza 1 i 2 (hdac1-2) | |
| JP7801223B2 (ja) | Ｃｄ２０６モジュレーター、その使用、および調製方法 | |
| JP2021504314A (ja) | Ｍｙｓｔファミリーヒストンアセチルトランスフェラーゼ阻害剤 | |
| CA2973773A1 (en) | 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| AU2020246317A1 (en) | Small-molecule inhibitor of PD-1/PD-L1, pharmaceutical composition thereof with PD-L1 antibody, and application of same | |
| Hu et al. | Discovery of highly potent and efficient CBP/p300 degraders with strong in vivo antitumor activity | |
| CN117567435A (zh) | 谷氨酰胺环化酶抑制剂及其应用 | |
| US10011598B2 (en) | Small molecules targeting repeat r(CGG) sequences | |
| AU2018244449A1 (en) | Agents for differentiating stem cells and treating cancer | |
| Song et al. | Proteolysis targeting chimera of BI-2536 induces potent dual degradation of PLK1 and BET proteins | |
| US20250376445A1 (en) | Compounds and methods for yap/tead modulation and indications therefor | |
| JP2006518726A (ja) | Ｇ四重鎖ｄｎａ構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用 | |
| WO2020263164A1 (en) | Compounds targeting dual g-quadruplex dna and stat3 | |
| RU2527459C1 (ru) | Новые лиганды g-квадруплексов на основе гетероаренантрацендионов, ингибирующие рост опухолевых клеток | |
| WO2017192228A1 (en) | Pak1 inhibitors and uses thereof | |
| WO2022272313A1 (en) | Modulators of histone acetyltransferase 1 and methods of treatment thereof | |
| HK1246287A1 (zh) | 用作irak抑制剂的哒嗪酮类大环化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250530 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250530 |